grapiprant and pembrolizumab

DRUG2 trials

Sponsors

Arrys Therapeutics

Conditions

Microsatellite Stable Colorectal CancerNon-small Cell Lung Cancer Adenocarcinoma

Phase 1

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

CompletedNCT03658772

Arrys TherapeuticsMicrosatellite Stable Colorectal Cancer

Start: 2018-09-20End: 2023-03-07Updated: 2023-10-24

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

TerminatedNCT03696212

Arrys TherapeuticsNon-small Cell Lung Cancer Adenocarcinoma

Start: 2019-01-08End: 2021-02-15Updated: 2021-02-21